Compare Stocks: CRBP, ORMP, and CUE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$3.44 +0.7%	$5.83	$2.81 ▼ $12.88	$71.81M	2.8	549,831 shs	170,426 shs
CUE Cue Biopharma	$15.50 -11.4%	$24.17	$4.97 ▼ $45.50	$109.26M	2.79	331,638 shs	156,425 shs
ORMP Oramed Pharmaceuticals	$3.84 -4.7%	$4.38	$2.25 ▼ $5.47	$159.87M	1.31	212,257 shs	51,518 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	-14.75%	+19.23%	-28.66%	-66.20%	-69.53%
CUE Cue Biopharma	-6.22%	-2.83%	-10.58%	-48.83%	-97.09%
ORMP Oramed Pharmaceuticals	-2.42%	+3.60%	-3.36%	-10.04%	+63.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$3.44 +0.7%	$5.83	$2.81 ▼ $12.88	$71.81M	2.8	549,831 shs	170,426 shs
CUE Cue Biopharma	$15.50 -11.4%	$24.17	$4.97 ▼ $45.50	$109.26M	2.79	331,638 shs	156,425 shs
ORMP Oramed Pharmaceuticals	$3.84 -4.7%	$4.38	$2.25 ▼ $5.47	$159.87M	1.31	212,257 shs	51,518 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	-14.75%	+19.23%	-28.66%	-66.20%	-69.53%
CUE Cue Biopharma	-6.22%	-2.83%	-10.58%	-48.83%	-97.09%
ORMP Oramed Pharmaceuticals	-2.42%	+3.60%	-3.36%	-10.04%	+63.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	2.71	Moderate Buy	$35.67	938.33% Upside
CUE Cue Biopharma	2.33	Hold	$83.00	435.45% Upside
ORMP Oramed Pharmaceuticals	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRBP, ORMP, and CUE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/12/2026	CRBP Corbus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$24.00 ➝ $23.00
11/11/2026	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform
10/23/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/15/2026	CRBP Corbus Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	CUE Cue Biopharma	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$83.00
9/18/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$83.00
9/17/2026	CUE Cue Biopharma	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy
9/14/2026	CRBP Corbus Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$35.00
9/8/2026	ORMP Oramed Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C+)
8/27/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$4.11 per share	N/A
CUE Cue Biopharma	$27.47M	4.10	N/A	N/A	$10.08 per share	1.54
ORMP Oramed Pharmaceuticals	$2M	79.87	$0.08 per share	45.52	$5.02 per share	0.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$78.54M	-$6.19	N/A	N/A	N/A	N/A	-100.96%	-82.70%	N/A
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-620.06%	-291.15%	N/A
ORMP Oramed Pharmaceuticals	$64.05M	$4.12	0.93	N/A	N/A	N/A	-5.17%	-4.54%	N/A

Latest CRBP, ORMP, and CUE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	ORMP Oramed Pharmaceuticals	$0.43	-$0.16	-$0.59	$0.43	N/A	N/A
11/10/2026	Q3 2026	CRBP Corbus Pharmaceuticals	-$1.27	-$1.81	-$0.54	-$1.81	$1.67 million	N/A
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
ORMP Oramed Pharmaceuticals	$0.25	6.51%	N/A	6.07%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	3.40	5.71
CUE Cue Biopharma	N/A	1.25	1.25
ORMP Oramed Pharmaceuticals	N/A	4.98	4.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
CUE Cue Biopharma	35.04%
ORMP Oramed Pharmaceuticals	12.73%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	3.50%
CUE Cue Biopharma	14.56%
ORMP Oramed Pharmaceuticals	20.77%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	36	20.61 million	18.02 million	Optionable
CUE Cue Biopharma	29	7.26 million	6.21 million	No Data
ORMP Oramed Pharmaceuticals	13	41.60 million	32.96 million	Optionable

CRBP, ORMP, and CUE Headlines

Recent News About These Companies

Lifeward Reports 18% Third-Quarter AlterG Revenue Growth and Provides Update on ReWalk Commercial Transition

2 hours ago | quiverquant.comQ

Oramed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 12 at 12:49 AM | marketscreener.comM

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

November 12 at 3:59 AM | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Lowered to Hold at Wall Street Zen

November 7, 2026 | americanbankingnews.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Cut to Hold at Wall Street Zen

November 7, 2026 | marketbeat.com

Oramed Pharmaceuticals (ORMP) Set to Release Earnings on Thursday

November 5, 2026 | americanbankingnews.com

Oramed Pharmaceuticals (ORMP) Expected to Release Quarterly Earnings on Thursday

November 5, 2026 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?

November 3, 2026 | marketbeat.com

Oramed Pharmaceuticals (NASDAQ:ORMP) Stock Breaks Below Two Hundred Day Moving Average - Time to Sell?

October 22, 2026 | marketbeat.com

Oramed Pharmaceuticals stock trades at USD 4.49 after insider sale

October 4, 2026 | ad-hoc-news.deA

Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Avraham Gabay Sells 20,000 Shares of Stock

October 3, 2026 | insidertrades.com

Oramed officer proposes USD 140,100 sale of Oramed Pharmaceuticals stock

October 2, 2026 | ad-hoc-news.deA

Oramed Pharmaceuticals consensus price target increased 12.00% to $7.14

September 15, 2026 | msn.com

Oramed: Q2 Earnings Snapshot

August 11, 2026 | chron.com

Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) CFO Sells $330,853.60 in Stock

July 3, 2026 | insidertrades.com

Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet

June 25, 2026 | prnewswire.com

ORMP: View inclusion in Russell indexes as positive that could raise awareness in investment community

June 18, 2026 | msn.com

Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes

June 17, 2026 | prnewswire.com

ORMP: Strategically acquiring interests in medtech & technology companies

June 8, 2026 | msn.com

Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction

May 22, 2026 | seekingalpha.com

Oramed Pharmaceuticals Inc.

May 18, 2026 | marketwatch.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, ORMP, and CUE Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$3.44 +0.03 (+0.73%)

As of 12:04 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Cue Biopharma NASDAQ:CUE

$15.50 -2.00 (-11.42%)

As of 12:04 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Oramed Pharmaceuticals NASDAQ:ORMP

$3.84 -0.19 (-4.71%)

As of 12:03 PM Eastern

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, ORMP, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, ORMP, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, ORMP, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, ORMP, and CUE Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

Cue Biopharma NASDAQ:CUE

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CRBP, ORMP, and CUE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CRBP, ORMP, and CUE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CRBP, ORMP, and CUE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP, ORMP, and CUE Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

Cue Biopharma NASDAQ:CUE

Oramed Pharmaceuticals NASDAQ:ORMP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools